Monoclonal antibodies were first identified as potential cancer treatments three decades ago, as the molecules could be engineered to bind to cancer cells and provoke an immune response against them. They have also proved useful for treating autoimmune disease and are under investigation as a treatment for many other conditions.
Monoclonal antibodies are now approved for treating cancers and autoimmune diseases, and nearly 200 are in clinical trials. Monoclonal antibodies bind only to specific target molecules, giving them a precision that many other drugs lack. These Y-shaped molecules, which are naturally produced by immune cells called B cells, have a nearly identical base but arms that can vary depending on their intended target. The arms bind precisely to the target while the base of the Y provides an anchor for circulating immune cells to attach to.
STAB VIDA offers Monoclonal Antibodies and Next-generation antibodies, that will create not just me-too products of existing protein therapeutics but me-better products through protein engineering. We help our clients explore exciting, next-generation antibody formats with superior properties as sources of blockbuster drugs. Formats of interest include antibody fragments, Fc fusion proteins, bispecific antibodies, multimodular antibodies, antibody mimetics, and T-cell receptors.
| I want to be contacted by a project manager |
